|ID||Components||Size (96 tests)||Size (480 tests)|
|A006-214||Human LDL R||35 μg||160 μg|
|A007-214||Biotinylated Human PCSK9||10 μg||10 μg|
|A003-214||Streptavidin-HRP||10 μg||10 μg|
|PC9-NA003||Anti-PCSK9 Neutralizing Antibody||40 μg||200 μg|
This pair is useful for screening for inhibitors of human PCSK9 binding to human LDL R.
Upon receipt, please store all items at -70℃.
After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 1 year in lyophilized state;
-70℃ for 1 year under sterile conditions after reconstitution
This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PCSK9 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human LDL R and in-house developed biotinylated PCSK9 protein. This product is uniquely suitable for rapid high-throughput screening of putative PCSK9 inhibitors. Briefly, we provide you with a biotinylated human PCSK9 protein, a human LDL R protein, an anti-PCSK9 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent. Your experiment will include 4 simple steps:
a) Coat the plate with human LDL R.
b) Add your molecule of interest to the plates.
c) Add human PCSK9-Biotin to the plates.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit PCSK9: LDL R binding will be determined by comparing OD readings among different experimental groups.
Binding of Biotinylated Human PCSK9 to Immobilized Human LDL R in a Functional ELISA Assay.
Immobilized human LDL R protein at 3 μg/mL (100 μL/well) can bind biotinylated human PCSK9 with a linear range of 0.000625-0.02 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting.
Inhibition of PCSK9 [Biotinylated] : LDL R Binding by Anti-PCSK9 Neutralizing Antibody.
Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL) were added into PCSK9: biotinylated LDL R binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
Price(USD) : $600.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.